FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2561794231> ?p ?o ?g. }

• W2561794231 abstract "Abstract Sensitization of leukemic cells with G- or GM-CSF may enhance the cytotoxicity of chemotherapy in younger adults with newly diagnosed acute myeloid leukemia (AML). In this multicenter randomized trial conducted by the Acute Leukemia French Association (ALFA), 259 patients (median age, 38 years; range: 15–50) were randomized at baseline to receive a timed-sequential induction (DNR 80mg/m2/d d1-3, AraC 500mg/m2/d d1-3 and 500mg/m2/12h d8-10, Mitox 12mg/m2/d d8-9) either without (135 patients) or with GM-CSF (124 patients) administered i.v. at 5μg/kg/d from day 1 to day 10. Patients reaching remission (eventually after salvage therapy) and not eligible for allogeneic stem cell transplantation were then randomized to compare the timed-sequential ALFA-9000 consolidation (Mitox 12mg/m2/d d1-3, VP16 200mg/m2/d d8-10, AraC 500mg/m2/d d1-3, 8-10) to the CALGB postremission chemotherapy, which includes 4 cycles of high-dose AraC (3g/m2/12h d1,3,5) followed by 4 additional DNR/AraC courses. Patients initially randomized in the GM-CSF arm received GM-CSF concurrently with chemotherapy during all cycles of consolidation therapy. First published results were encouraging showing that priming of leukemic cells with GMCSF is a means of enhancing the efficacy of chemotherapy in younger adults with AML (Thomas et al., Leukemia 2007). The effects of GM-CSF on EFS and according to distinct biological subgroups are reported herein with a longer follow-up. A significantly higher CR rate was observed after induction chemotherapy in patients primed with GM-CSF (88% for patients receiving GM-CSF versus 78% for those not receiving GM-CSF; p = 0.04). With a median follow-up of 5.4 years, the EFS rate was confirmed to be better in the GM-CSF group (43% vs 34%; p = 0.04). However, the difference between the two arms remained not statistically different in terms of OS. GM-CSF did not improve the outcome in the subgroups with favorable cytogenetics constituted by CBF leukemias (61% at 5 years in the GM-CSF group vs 62% in the non GM-CSF group; p = 0.9). Research in defining prognostic factors has moved from classical cytogenetic to an examination of molecular markers. Molecular markers are particularly important for patients with AML and a normal karyotype, identifying within this group two genotypes, NPM1+ FLT3-ITD− and CEBPA+ FLT3-ITD−, with a relatively favorable outcome which were classified here as intermediate-1. In the present study cohort, these intermediate-1 genotypes were associated with a risk profile comparable with that of CBF AML (5-year EFS at 67%). Comportment after priming with GM-CSF was also comparable showing no difference in terms of long-term EFS compared to absence of priming. Although results were not statistically significant, patients with intermediate-risk cytogenetics other than intermediate-1, referred here as intermediate-2, and patients with unfavorable cytogenetics benefited from GM-CSF therapy (5-year EFS, 24% vs 18%, p = 0.2). The benefit of GM-CSF was in part related to a higher proportion rate of CR after the initial course of induction chemotherapy (89% vs 67%, p = 0.04) for unfavorable cytogenetics and a trend for a lower relapse rate (38% vs 52%) in intermediate-2 patients. It appeared that the difference in terms of EFS probability in this population resulted from GM-CSF-mediated activation of subpopulations of leukemic cells that were initially the more proliferative. Actually, the effect of GM-CSF became significant when considering only patients with higher initial WBC count (> 10 × 109/l) (5-year EFS, 32% vs 5%, p = 0.003), while there was no difference in patients with lower initial WBC count (< 10 × 109/l). Among frequent mutations observed in AML, FLT3-ITD provides a proliferative advantage to a population in which normal maturation is blocked. Similarly, MLL fusion proteins also confer a remarkable growth/survival advantage. When combining these two abnormalities for comparison of the effect of GM-CSF priming, the difference in terms of EFS was highly significant (5-year EFS, 39% with GM-CSF vs 8% without GM-CSF in the population of patients FLT3-ITD or MLL positive, p = 0.005). The results of priming in the ALFA-9802 trial confirm that chemotherapy and sensitization of leukemic cells and their progenitors by GM-CSF is a plausible strategy for improving the outcome of younger patients with newly diagnosed AML particularly for those with intermediate-2 or unfavorable cytogenetics displaying higher proliferative features." @default.
• W2561794231 created "2017-01-06" @default.
• W2561794231 creator A5000000264 @default.
• W2561794231 creator A5000436961 @default.
• W2561794231 creator A5010517016 @default.
• W2561794231 creator A5014838075 @default.
• W2561794231 creator A5017435311 @default.
• W2561794231 creator A5018416096 @default.
• W2561794231 creator A5022341207 @default.
• W2561794231 creator A5028365885 @default.
• W2561794231 creator A5028508696 @default.
• W2561794231 creator A5034726747 @default.
• W2561794231 creator A5045283637 @default.
• W2561794231 creator A5046391226 @default.
• W2561794231 creator A5050799774 @default.
• W2561794231 creator A5054745373 @default.
• W2561794231 creator A5057405519 @default.
• W2561794231 creator A5058825074 @default.
• W2561794231 creator A5064103067 @default.
• W2561794231 creator A5078817313 @default.
• W2561794231 creator A5079742903 @default.
• W2561794231 creator A5087870886 @default.
• W2561794231 date "2008-11-16" @default.
• W2561794231 modified "2023-10-14" @default.
• W2561794231 title "Which AML Subsets Benefit from Leukemic Cell Priming during Chemotherapy? Long-Term Analysis of the ALFA-9802 GM-CSF Study" @default.
• W2561794231 doi "https://doi.org/10.1182/blood.v112.11.765.765" @default.
• W2561794231 hasPublicationYear "2008" @default.
• W2561794231 type Work @default.
• W2561794231 sameAs 2561794231 @default.
• W2561794231 citedByCount "0" @default.
• W2561794231 crossrefType "journal-article" @default.
• W2561794231 hasAuthorship W2561794231A5000000264 @default.
• W2561794231 hasAuthorship W2561794231A5000436961 @default.
• W2561794231 hasAuthorship W2561794231A5010517016 @default.
• W2561794231 hasAuthorship W2561794231A5014838075 @default.
• W2561794231 hasAuthorship W2561794231A5017435311 @default.
• W2561794231 hasAuthorship W2561794231A5018416096 @default.
• W2561794231 hasAuthorship W2561794231A5022341207 @default.
• W2561794231 hasAuthorship W2561794231A5028365885 @default.
• W2561794231 hasAuthorship W2561794231A5028508696 @default.
• W2561794231 hasAuthorship W2561794231A5034726747 @default.
• W2561794231 hasAuthorship W2561794231A5045283637 @default.
• W2561794231 hasAuthorship W2561794231A5046391226 @default.
• W2561794231 hasAuthorship W2561794231A5050799774 @default.
• W2561794231 hasAuthorship W2561794231A5054745373 @default.
• W2561794231 hasAuthorship W2561794231A5057405519 @default.
• W2561794231 hasAuthorship W2561794231A5058825074 @default.
• W2561794231 hasAuthorship W2561794231A5064103067 @default.
• W2561794231 hasAuthorship W2561794231A5078817313 @default.
• W2561794231 hasAuthorship W2561794231A5079742903 @default.
• W2561794231 hasAuthorship W2561794231A5087870886 @default.
• W2561794231 hasConcept C126322002 @default.
• W2561794231 hasConcept C143998085 @default.
• W2561794231 hasConcept C168563851 @default.
• W2561794231 hasConcept C2776611710 @default.
• W2561794231 hasConcept C2776694085 @default.
• W2561794231 hasConcept C2776863199 @default.
• W2561794231 hasConcept C2778041864 @default.
• W2561794231 hasConcept C2778336483 @default.
• W2561794231 hasConcept C2778461978 @default.
• W2561794231 hasConcept C2778729363 @default.
• W2561794231 hasConcept C2911091166 @default.
• W2561794231 hasConcept C71924100 @default.
• W2561794231 hasConcept C90924648 @default.
• W2561794231 hasConceptScore W2561794231C126322002 @default.
• W2561794231 hasConceptScore W2561794231C143998085 @default.
• W2561794231 hasConceptScore W2561794231C168563851 @default.
• W2561794231 hasConceptScore W2561794231C2776611710 @default.
• W2561794231 hasConceptScore W2561794231C2776694085 @default.
• W2561794231 hasConceptScore W2561794231C2776863199 @default.
• W2561794231 hasConceptScore W2561794231C2778041864 @default.
• W2561794231 hasConceptScore W2561794231C2778336483 @default.
• W2561794231 hasConceptScore W2561794231C2778461978 @default.
• W2561794231 hasConceptScore W2561794231C2778729363 @default.
• W2561794231 hasConceptScore W2561794231C2911091166 @default.
• W2561794231 hasConceptScore W2561794231C71924100 @default.
• W2561794231 hasConceptScore W2561794231C90924648 @default.
• W2561794231 hasLocation W25617942311 @default.
• W2561794231 hasOpenAccess W2561794231 @default.
• W2561794231 hasPrimaryLocation W25617942311 @default.
• W2561794231 hasRelatedWork W2293799840 @default.
• W2561794231 hasRelatedWork W2389127605 @default.
• W2561794231 hasRelatedWork W243461658 @default.
• W2561794231 hasRelatedWork W2475196148 @default.
• W2561794231 hasRelatedWork W2519214558 @default.
• W2561794231 hasRelatedWork W2549388071 @default.
• W2561794231 hasRelatedWork W2550239652 @default.
• W2561794231 hasRelatedWork W2557201131 @default.
• W2561794231 hasRelatedWork W2557297391 @default.
• W2561794231 hasRelatedWork W2559335953 @default.
• W2561794231 hasRelatedWork W2559699313 @default.
• W2561794231 hasRelatedWork W2562349582 @default.
• W2561794231 hasRelatedWork W2586037095 @default.
• W2561794231 hasRelatedWork W2594349340 @default.
• W2561794231 hasRelatedWork W2907581557 @default.
• W2561794231 hasRelatedWork W2907601693 @default.
• W2561794231 hasRelatedWork W2953094268 @default.
• W2561794231 hasRelatedWork W2979295472 @default.
• W2561794231 hasRelatedWork W2979382939 @default.
• W2561794231 hasRelatedWork W2979776894 @default.

• next